Cargando…

Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma

BACKGROUND: Previous studies have demonstrated that PANoptosis is strongly correlated with cancer immunity and progression. This study aimed to develop a PANoptosis-related signature (PANRS) to explore its potential value in predicting the prognosis and immunotherapy response of hepatocellular carci...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Jinfeng, Huang, Qian, Peng, Xingyu, Luo, Chen, Liu, Zitao, Liu, Dongdong, Yuan, Huazhao, Yuan, Rongfa, Cheng, Xuexin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471990/
https://www.ncbi.nlm.nih.gov/pubmed/37662906
http://dx.doi.org/10.3389/fimmu.2023.1218661
_version_ 1785099975838924800
author Zhu, Jinfeng
Huang, Qian
Peng, Xingyu
Luo, Chen
Liu, Zitao
Liu, Dongdong
Yuan, Huazhao
Yuan, Rongfa
Cheng, Xuexin
author_facet Zhu, Jinfeng
Huang, Qian
Peng, Xingyu
Luo, Chen
Liu, Zitao
Liu, Dongdong
Yuan, Huazhao
Yuan, Rongfa
Cheng, Xuexin
author_sort Zhu, Jinfeng
collection PubMed
description BACKGROUND: Previous studies have demonstrated that PANoptosis is strongly correlated with cancer immunity and progression. This study aimed to develop a PANoptosis-related signature (PANRS) to explore its potential value in predicting the prognosis and immunotherapy response of hepatocellular carcinoma (HCC). METHODS: Based on the expression of PANoptosis-related genes, three molecular subtypes were identified. To construct a signature, the differentially expressed genes between different molecular subtypes were subjected to multivariate least absolute shrinkage and selection operator Cox regression analyses. The risk scores of patients in the training set were calculated using the signature. The patients were classified into high-risk and low-risk groups based on the median risk scores. The predictive performance of the signature was evaluated using Kaplan-Meier plotter, receiving operating characteristic curves, nomogram, and calibration curve. The results were validated using external datasets. Additionally, the correlation of the signature with the immune landscape and drug sensitivity was examined. Furthermore, the effect of LPCAT1 knockdown on HCC cell behavior was verified using in vitro experiments. RESULTS: This study developed a PANRS. The risk score obtained by using the PANRS was an independent risk factor for the prognosis of patients with HCC and exhibited good prognostic predictive performance. The nomogram constructed based on the risk score and clinical information can accurately predicted the survival probability of patients with HCC. Patients with HCC in the high-risk groups have high immune scores and tend to generate an immunosuppressive microenvironment. They also exhibited a favorable response to immunotherapy, as evidenced by high tumor mutational burden, high immune checkpoint gene expression, high human leukocyte antigen gene expression, low tumor immune dysfunction and low exclusion scores. Additionally, the PANRS enabled the identification of 15 chemotherapeutic agents, including sorafenib, for patients with HCC with different risk levels, guiding clinical treatment. The signature gene LPCAT1 was upregulated in HCC cell lines. LPCAT1 knockdown markedly decreased HCC cell proliferation and migration. CONCLUSION: PANRS can accurately predict the prognosis and immunotherapy response of patients with HCC and consequently guide individualized treatment.
format Online
Article
Text
id pubmed-10471990
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104719902023-09-02 Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma Zhu, Jinfeng Huang, Qian Peng, Xingyu Luo, Chen Liu, Zitao Liu, Dongdong Yuan, Huazhao Yuan, Rongfa Cheng, Xuexin Front Immunol Immunology BACKGROUND: Previous studies have demonstrated that PANoptosis is strongly correlated with cancer immunity and progression. This study aimed to develop a PANoptosis-related signature (PANRS) to explore its potential value in predicting the prognosis and immunotherapy response of hepatocellular carcinoma (HCC). METHODS: Based on the expression of PANoptosis-related genes, three molecular subtypes were identified. To construct a signature, the differentially expressed genes between different molecular subtypes were subjected to multivariate least absolute shrinkage and selection operator Cox regression analyses. The risk scores of patients in the training set were calculated using the signature. The patients were classified into high-risk and low-risk groups based on the median risk scores. The predictive performance of the signature was evaluated using Kaplan-Meier plotter, receiving operating characteristic curves, nomogram, and calibration curve. The results were validated using external datasets. Additionally, the correlation of the signature with the immune landscape and drug sensitivity was examined. Furthermore, the effect of LPCAT1 knockdown on HCC cell behavior was verified using in vitro experiments. RESULTS: This study developed a PANRS. The risk score obtained by using the PANRS was an independent risk factor for the prognosis of patients with HCC and exhibited good prognostic predictive performance. The nomogram constructed based on the risk score and clinical information can accurately predicted the survival probability of patients with HCC. Patients with HCC in the high-risk groups have high immune scores and tend to generate an immunosuppressive microenvironment. They also exhibited a favorable response to immunotherapy, as evidenced by high tumor mutational burden, high immune checkpoint gene expression, high human leukocyte antigen gene expression, low tumor immune dysfunction and low exclusion scores. Additionally, the PANRS enabled the identification of 15 chemotherapeutic agents, including sorafenib, for patients with HCC with different risk levels, guiding clinical treatment. The signature gene LPCAT1 was upregulated in HCC cell lines. LPCAT1 knockdown markedly decreased HCC cell proliferation and migration. CONCLUSION: PANRS can accurately predict the prognosis and immunotherapy response of patients with HCC and consequently guide individualized treatment. Frontiers Media S.A. 2023-08-18 /pmc/articles/PMC10471990/ /pubmed/37662906 http://dx.doi.org/10.3389/fimmu.2023.1218661 Text en Copyright © 2023 Zhu, Huang, Peng, Luo, Liu, Liu, Yuan, Yuan and Cheng https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zhu, Jinfeng
Huang, Qian
Peng, Xingyu
Luo, Chen
Liu, Zitao
Liu, Dongdong
Yuan, Huazhao
Yuan, Rongfa
Cheng, Xuexin
Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma
title Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma
title_full Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma
title_fullStr Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma
title_full_unstemmed Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma
title_short Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma
title_sort identification of molecular subtypes based on panoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471990/
https://www.ncbi.nlm.nih.gov/pubmed/37662906
http://dx.doi.org/10.3389/fimmu.2023.1218661
work_keys_str_mv AT zhujinfeng identificationofmolecularsubtypesbasedonpanoptosisrelatedgenesandconstructionofasignatureforpredictingtheprognosisandresponsetoimmunotherapyresponseinhepatocellularcarcinoma
AT huangqian identificationofmolecularsubtypesbasedonpanoptosisrelatedgenesandconstructionofasignatureforpredictingtheprognosisandresponsetoimmunotherapyresponseinhepatocellularcarcinoma
AT pengxingyu identificationofmolecularsubtypesbasedonpanoptosisrelatedgenesandconstructionofasignatureforpredictingtheprognosisandresponsetoimmunotherapyresponseinhepatocellularcarcinoma
AT luochen identificationofmolecularsubtypesbasedonpanoptosisrelatedgenesandconstructionofasignatureforpredictingtheprognosisandresponsetoimmunotherapyresponseinhepatocellularcarcinoma
AT liuzitao identificationofmolecularsubtypesbasedonpanoptosisrelatedgenesandconstructionofasignatureforpredictingtheprognosisandresponsetoimmunotherapyresponseinhepatocellularcarcinoma
AT liudongdong identificationofmolecularsubtypesbasedonpanoptosisrelatedgenesandconstructionofasignatureforpredictingtheprognosisandresponsetoimmunotherapyresponseinhepatocellularcarcinoma
AT yuanhuazhao identificationofmolecularsubtypesbasedonpanoptosisrelatedgenesandconstructionofasignatureforpredictingtheprognosisandresponsetoimmunotherapyresponseinhepatocellularcarcinoma
AT yuanrongfa identificationofmolecularsubtypesbasedonpanoptosisrelatedgenesandconstructionofasignatureforpredictingtheprognosisandresponsetoimmunotherapyresponseinhepatocellularcarcinoma
AT chengxuexin identificationofmolecularsubtypesbasedonpanoptosisrelatedgenesandconstructionofasignatureforpredictingtheprognosisandresponsetoimmunotherapyresponseinhepatocellularcarcinoma